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Purpose:  The aim of this study was to generate normal tissue complication probability (NTCP) models 
in patients treated with either proton beam therapy (PBT) or intensity-modulated radiotherapy (IMRT) for 
oropharynx cancer, and to use a model-based approach to investigate the added value of PBT in 
preventing treatment complications. 
Methods: For patients with advanced-stage oropharynx cancer, treated with curative intent (PBT, n=30; 
IMRT, n=175), NTCP models were developed using multivariable logistic regression analysis with 
backward selection. For PBT-treated patients, an equivalent IMRT plan was generated, to serve as a 
reference to determine the benefit of PBT in terms of NTCP. The models were then applied to the PBT 
treated patients to compare predicted and observed clinical outcomes (calibration-in-the large).  Five 
binary endpoints were analyzed at 6-months post-treatment: dysphagia ≥ grade 2, dysphagia ≥ grade 3, 
xerostomia ≥ grade 2, salivary duct inflammation ≥ grade 2, and feeding tube dependence. Corresponding 
toxicity grading was based on CTCAEv4. Paired t-tests and Wilcoxon rank tests were used to compare 
mean NTCP results for endpoints between PBT and IMRT. 
Results: NTCP models developed based on outcomes from all patients were applied to those receiving 
PBT. NTCP-values were calculated for the equivalent IMRT plans for all PBT treated patients, revealing 
significantly higher NTCP-values with IMRT. PBT was associated with statistically significant reductions 
in the mean NTCP values for each endpoint at 6-months post treatment, with the largest absolute 
differences in rates of > grade 2 dysphagia and > grade 2 xerostomia. 
Conclusion:  NTCP models predict significant improvements in the probability of short-term, treatment-
related toxicity with PBT compared to IMRT for oropharyngeal cancer. This study demonstrated an  
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INTRODUCTION 
Currently most patients diagnosed with oropharyngeal head and neck carcinoma are cured after 
undergoing definitive multimodality therapy [1, 2]. Despite technological advances in head and neck 
radiotherapy, many patients experience long-term severe toxicities that negatively impact quality of life 
[3-7].   
Data from single institution series have demonstrated advantages of proton beam therapy (PBT) 
over intensity-modulated radiotherapy (IMRT), due to PBT’s favorable dose deposition beam profile that 
improves sparing of organs at risk and reduces integral dose to the patient [8-12]. As a result, randomized 
trials are ongoing to provide level I evidence regarding the clinical benefit of PBT [13].  Completing 
comparative randomized trials for new treatment technology remains challenging due to pre-existing 
patient preferences for selected treatments, high costs of conducting research, and potential ethical 
considerations related to clinician equipoise [14].  Moreover, in an era of personalized medicine with 
ever-increasing patient and tumor data heterogeneity, traditional level I evidence may not always 
adequately support individualized clinical decision making [15]. Data derived from statistical modeling of 
clinical outcomes for individual patients, can provide complementary data regarding the comparative 
effectiveness of treatment approaches in question. A model-based approach may be a cost-effective 
strategy to quantify clinical gains with PBT via estimation of potential reduction in normal tissue 
complication probability (NTCP) [16]. Such an approach may be optimal in informing patient eligibility 
for a chosen therapy to enhance clinical outcomes and cost efficiency [17]. 
To date, only one study evaluated NTCP models for PBT in a heterogeneous group of head and 
neck patients [18]. The aim of this study was to generate multivariable normal tissue complication 















hypothesize that improvements in dosimetric normal tissue sparing with PBT will translate to lower 















METHODS AND MATERIALS 
Study population 
This (institution review board approved) study included patients with locally-advanced 
oropharyngeal carcinoma treated with curative intent multi-modality therapy from two institutions who 
had at least one year of follow-up. The cohort from the XXXXX consisted of 30 patients with 
oropharyngeal carcinoma treated with surgery followed by adjuvant proton radiotherapy, with or without 
chemotherapy (decision to offer chemotherapy was consistent with standard of care, such as the presence 
of positive margin and/or extranodal extension [19]) between 2013 and 2016. The cohort from the 
XXXXXX consisted of 175 patients mainly with locally-advanced oropharyngeal carcinoma treated with 
definitive photon radiotherapy with or without chemotherapy..  
  
Treatment 
 Patients in the postoperative cohort from XXXXX underwent radiotherapy planning at 
approximately 3-4 weeks after surgery. The process of computed tomography (CT) simulation 
acquisition, target delineation and treatment planning has been previously described [9]. For these 
patients, PBT plans (which were the ones clinically delivered to the patients) were generated for treatment 
delivery using pencil-beam scanning (PBS) via single field uniform dosing, plus an accompanying IMRT 
(VMAT) plan which was clinically reviewed and deemed acceptable for treatment (but not delivered, as 
they were reserved as a contingency plan only in case of unexpected proton beam unavailability) [9]. 
These accompanying IMRT plans needed to meet all of the coverage goals and organ sparing constraints 
similar to patients who receive the entirety of their radiotherapy via IMRT. For patients receiving organ-

















Dosimetric data collection and extraction 
For each patient, relevant organs-at-risk (OARs) were contoured as previously described [21, 22].  
Target delineation was consistent with standard of care in both postoperative and definitive RT patients, 
and no patients were enrolled or treated on protocols involving omission or reduction of standardly 
defined clinical targets. OARs were bilateral parotid glands, inferior, middle and superior pharyngeal 
constrictor muscles (PCM), supraglottic larynx, and oral cavity. All plans and structures were centrally 
reviewed and modified as needed to reflect uniformity and consistency across both institutions. The 
following dose volume histogram (DVH) parameters were collected for OARs: minimum dose, maximum 
dose, mean dose, V5Gy, V10Gy, V20Gy, V30Gy, V40Gy, V50Gy, V60Gy and V70Gy (percent volume 
receiving 5Gy, 10 Gy, 20 Gy, 30 Gy, 40 Gy, 50 Gy, 60 Gy and 70 Gy). DVH parameters were extracted 
by MIRADA-software (Oxford Centre for Innovation UK) from both the XXXX PBT and IMRT plans 




 After completion of therapy, patients were followed with clinical examinations and head and neck 
imaging, initially with a 3-month post-treatment PET-CT, then PET-CT or CT every 3-6 months for the 
first 2 years, and then every 6-12 months thereafter. Toxicity data was collected before the start of 
radiotherapy and at every follow-up visit and graded using CTCAE version 4.0. 
 
Endpoints  
 The following toxicity endpoints were defined at 6 months from treatment completion: (1) 
Dysphagia ≥ grade 2; (2) dysphagia ≥ grade 3; (3) xerostomia ≥ grade 2; (4) salivary duct inflammation ≥ 















1 = slightly thickened saliva; slightly altered taste; Grade 2 = thick, ropy, sticky saliva; markedly altered 
taste; alteration in diet indicated; secretion-induced symptoms; limiting instrumental activities of daily 
living (ADL); Grade 3 = acute salivary gland necrosis; sever secretion-induced symptoms; tube feeding 
indicated; limiting self-care ADL; disabling; Grade 4 = life-threatening consequences; urgent intervention 
indicated; Grade 5 = death. 
 
The 6-month endpoint was chosen, given that this was the time point for which the largest amount of 




Patients who had one of the endpoints already at baseline, were excluded from the analyses 
regarding that particular endpoint. For each endpoint, multivariable NTCP models were created. 
Univariable logistic regression analyses and correlation statistics were performed to select candidate 
predictors for each endpoint that were significantly associated with the endpoints in univariable analysis 
(p < 0.05), but not mutually correlated (r < 0.80). Then, a stepwise backward multivariable logistic 
regression procedure was used to exclude the variables with p > 0.157 from the model. The resulting 
model was then manually explored further in two ways: 1) by testing whether the models would 
significantly deteriorate when one or more variables would be removed; 2) by exchanging the selected 
dose volume variables by other potentially relevant dose variables that were highly correlated to the 
selected dose variable and therefore discarded in an earlier stage. The final best model was chosen 
primarily by the applying the likelihood-ratio test, but also by evaluating the general model performance 
measures, i.e., ROC-area under the curve, discrimination slope, explained variance and calibration. For 















correct (shrink) the models (slope and intercept) for optimism. This was done to obtain realistic regression 
coefficients for the model variables that are representative for populations like the development sample. A 
figure summarizing the steps in model generation is shown in Figure 1.  
Candidate variables that were initially entered in the model were: gender (male versus female), 
age (as continuous variable), concomitant chemotherapy (no vs. yes), weight loss at baseline (0-10 vs. 
>10%), accelerated radiotherapy (no vs. yes), T-stage (stage 1-2 vs. 3-4), N-stage (negative vs. positive), 
target volume (local/unilateral vs. bilateral neck irradiation), surgery (no vs. yes), and baseline toxicities 
(grade 0 vs. grade 1). Paired t-tests and Wilcoxon rank tests were used to compare mean NTCP results for 
endpoints between PBT and IMRT. Data were analyzed using SPSS Statistics for Windows, version 23. 
 
NTCP calculation 
NTCP values were determined for each patient at all endpoints in both PBT and photon plans using the 
NTCP formulae [23]: NTCP = 	 
(	)
  with the linear predictor (S) for complications defined as:  
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Patient and treatment characteristics, observed rates of toxicities at 6-months with corresponding OAR 
mean doses for relevant endpoints of the 2 patient cohorts are shown in Table 1. The difference in 
increased sparing of an organ at risk, such as the oral cavity, is shown in Figure 2. A summary of all 
model performance results for all endpoints is shown in Table 2, which presents the uncorrected 
(apparent) modeling results, with uncorrected regression coefficients.  
The final NTCP models for the endpoints below were developed based on outcomes of each endpoint 
from all patients, and include the corrected coefficients (after internal validation).  
(1) Dysphagia ≥ grade 2 at 6 months: S= -4.3477 + (0.0345 * contralateral parotid mean dose (Gy)) 
+ (0.0524 * oral cavity mean dose (Gy)). 
(2) Dysphagia ≥ grade 3 at 6 months: S= -4.3188 + (1.3744 * T3 or 4) + (1.0222 * baseline weight 
loss >10%) + (0.0385 * oral cavity mean dose (Gy)).  
(3) Xerostomia ≥ grade 2 at 6 months: S= -3.6891 + (0.8639 * baseline xerostomia grade 1) + 
(0.6423* concomitant chemotherapy) + (0.0520 * oral cavity mean dose (Gy)). 
(4) Salivary Duct Inflammation ≥ grade 2 at 6 months: S= -6.3436 + (0.0389 * Age (years)) + 
(1.0231* accelerated radiotherapy) + (0.0367 * oral cavity mean dose (Gy)). 
(5) Tube feeding dependence at 6 months: S= -10.3690 + (1.3848 * T3 or 4) + (1.3805* baseline 
weight loss >10%) + (0.0364 * PCM inferior mean dose (Gy)) + (0.0939* PCM superior mean 
dose (Gy)). 
 
The NTCP-values were calculated for the equivalent IMRT plans for all PBT treated patients, revealing 
significantly higher NTCP-values for the IMRT plans for all endpoints (Table 3). PBT was associated 















post treatment, with the largest absolute differences in rates of > grade 2 dysphagia and xerostomia 
(Table 3). The absolute reductions in individual patient NTCP by PBT as compared to IMRT ranged 
from 2 to 14% for grade 2 dysphagia, 1 to 8% for grade 3 dysphagia, 2 to 17% for grade 2 xerostomia, 1 

































Although IMRT has led to reduction of radiation induced side effects with improved global 
quality of life from 3D-conformal techniques, efforts are still needed to further enhance the therapeutic 
ratio in oropharyngeal carcinoma after multimodality curative therapy [24-27]. It is for this reason that 
proton therapy, with its ability to improve normal tissue sparing when compared to IMRT, may help to 
improve patient toxicity outcomes and long-term quality of life. However, precise estimates of the clinical 
impact of PBT are lacking with the current absence of randomized data. The present study evaluates 
toxicity outcomes between IMRT to PBT using normal tissue complication probability models in order to 
estimate potential clinical benefits of PBT using a large cohort of patients receiving radiotherapy for 
oropharyngeal carcinoma.  
Our study extends the existing literature regarding the comparative effectiveness of PBT  for head 
and neck radiotherapy and is the first report of such a comparative analysis limited to patients with 
oropharynx cancer, in whom high rates of long-term survival emphasize a focus on toxicity mitigation to 
preserve quality of life [1, 28]. Treatment-related late complications that commonly affect quality of life 
in these patients are mainly dysphagia, gastrostomy-tube dependence, and xerostomia [29, 30]. In this 
study, NTCP models were developed using patient cohorts from 2 institutions treated with IMRT and 
PBT, respectively. The NTCP models were then applied to all patients receiving PBT, for whom each had 
a treatment-approved ‘backup’ IMRT plan. Thus, each PBT patient served as an internal control when 
comparing estimated toxicity from PBT vs IMRT, which we believe to be a unique strength of the study. 
Four toxicity domains (ie. dysphagia, xerostomia, salivary duct inflammation, and G-tube dependence) 
were evaluated and modeled at 6 months from completion of PBT. Results herein demonstrated 
significant reduction of predicted complications in all evaluated head and neck treatment-related 















With the introduction of new technologies in radiation delivery, coupled with its potential significant 
costs, it is important to assess and confirm that new technologies for radiation delivery will lead to 
meaningful gains for patients. The gold standard for such an effort remains a prospective, randomized 
trial; however, barriers to successful implementation of such a trial exist, and will likely remain for 
current and future efforts. Our study represents a novel approach that can be used currently to assess 
potential benefits while we await the results of prospective trials.  
This study has some limitations to warrant mention. First, even though our data suggests that 
proton therapy may be a method by which treatment-related toxicity can be improved, it does not 
specifically address the issue of cost effectiveness. The issue of cost effectiveness and justification of new 
technologies is a much more complex issue, which is outside the limits of this study, and will have to be 
addressed by future, collective efforts. Second, the PBT cohort was limited to only 30 patients, and the 
cohorts from each institution were dissimilar in that one institution largely treated patients with an initial 
surgical approach followed by adjuvant radiotherapy (+/- chemotherapy), while the other institution 
largely treated patients with multimodality organ preservation. We acknowledge that the different 
approaches may itself affect patient toxicity outcomes.  However, our model was generated using data 
and outcomes from the entire cohort from both institutions, incorporating patients receiving a range of 
accepted treatment approaches, which may allow for this model to be generalizable for allowable 
treatment approaches. Finally, our model overpredicted the rate of xerostomia compared to observed 
prevalence for patients receiving proton therapy. While we would prefer, given a choice, that such models 
overpredict rather than underpredict toxicity for proton therapy, it is clear that clinical validation of this 
model in a larger group of patients, receiving a range of accepted treatment approaches, is needed.  This is 
already in progress, as patients at one of the participating institutions in this study is selecting and treating 
patients with proton therapy for oropharynx cancer based on these models. The results and clinical 
validation from current patient treatments will be a natural follow-up to this initial effort, and will be 















In summary, this study demonstrates the potential value of NTCP model based approaches in 
comparing predicted patient outcomes. Such a tool may be highly useful when randomized data are not 
available, or when deciding on which patients may be most likely to benefit from the use of a limited 
resource. Results of the current study may serve as a guide to patient selection, and provide 
complementary data regarding estimated clinical effectiveness of PTV when results from properly 
conducted phase III trials are not available [13, 14]. A model-based approach can also be incorporated 
into the context of a prospective, randomized trial, either as a potential outcome biomarker, or as criteria 
to best select patients for trial enrollment. In the end, we as radiation oncologists believe that our mission 
is to improve the lives of our patients, and to apply advances in our field in a feasible and judicious 
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Figure 1: Variable selection and logistic regression modeling for each endpoint 
 
Figure 2: IMRT vs. PBT Comparison: axial (left) and sagittal (right) slices of representative radiation 
plans for adjuvant radiation therapy in a patient with T1N2aM0 stage IVA (7th edition) base of tongue 
carcinoma, showing IMRT and PBT radiation plans (60Gy in 30 fractions) for the same patient. The PBT 
plan demonstrates lower dose to oral cavity structures compared to IMRT.  
 
Figure 3. Waterfall plots showing illustrating individual reduction in NTCP for (A) Dysphagia grade ≥2, 
(B) Dysphagia grade ≥3, (C) Xerostomia ≥grade 2, (D) Salivary duct inflammation grade ≥2, and (E) 




















  Number  % Number  % *SMD p value 
Neck RT Bilateral 29 96.70% 155 88.60% -0.31 0.05 
 Male 26 86.70% 112 64.00% -0.55 0.003 
 Robotic Surgery 
Primary Site 29 96.70% 0 0.00% -7.66 
< 0.001 
 Extensive Surgery 
Primary Site* 1 3.30% 1 0.60% -0.20 
0.42 
 Surgery neck* 30 100.00% 3 1.70% -10.75 < 0.001 
 Concomitant 
chemotherapy 7 23.30% 101 57.70% 0.75 
< 0.001 
 T3 or T4 5 16.70% 90 51.40% 0.79 < 0.001 
 Node positive 29 96.70% 135 77.60% -0.60 < 0.001 
 Pre-Treatment 
Weight loss >10% 2 6.70% 14 8.40% 0.06 
0.75 
 Accelerated (6 
fraction per week) 
RT 
3 10.00% 54 30.90% 0.54 0.002 
 Dysphagia 
CTCAEv4 ≥G2 at 
Baseline 
0 0.00% 46 26.30% 0.84 < 0.001 
 Dysphagia 
CTCAEv4 ≥G2 at 
6 Months 
2 6.70% 84 48.00% 1.04 < 0.001 
 Dysphagia 
CTCAEv4 ≥G3 at 
6 Months 

















CTCAEv4 ≥G1 at 
Baseline 
4 13.30% 24 13.70% 0.01 0.96 
 Xerostomia 
CTCAEv4 ≥G2 at 
6 Months 
0 0.00% 80 46.20% 1.31 < 0.001 
 Salivary Duct 
Inflammation 
CTCAEv4 ≥G1 at 
Baseline 
1 3.30% 23 13.10% 0.36 0.02 
 Salivary Duct 
Inflammation 
CTCAEv4 ≥G2 at 
6 Months 
1 3.30% 31 17.90% 0.49 0.001 
 Tube feeding 
dependence at 6 
months 
0 0.00% 36 20.60% 0.72 < 0.001 
 
  
          
  
 AVERAGE 
VALUES           
 
 Age (years) 58.2 ± 11.8 
  
60.1 ± 8.7 
  
0.18 0.40 
 High Risk PTV 
Prescribed dose 
(Gy) 
62.2 ± 2.7 
  
69.8 ± 2.2 
  
3.09 < 0.001 
 Parotid ipsilateral 





13.6 ± 5.7 
  
29.1 ± 10.6 
  
1.82 < 0.001 
 PCM inferior 
mean dose (Gy) 29.1 ± 6.6   47.0 ± 13.0   1.74 
< 0.001 
 PCM superior 















Oral cavity mean 




RT=radiotherapy; G2/3=grade 2 or 3 common toxicity Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0; PTV=planning 
tumor volume; PCM=pharyngeal constrictor muscles; SMD = standardized mean difference 
 
* In the photon cohort, 1 patient received open (non-robotic ) surgery to the primary site (without neck surgery), 3 patients received neck surgery 












































TABLE 2. Model Summary Results 
 
Measures  












Events Controls 107 147 118 163 162 
 Events* 52 (33%) 37 (20%) 76 (39%) 31 (16%) 34 (17%) 
       
Overall Nagelkerke 
adjusted R2 0.206 0.248 0.204 0.140 0.403 
       
Discrimination ROC-curve 












slope 0.152 0.179 0.142 0.089 0.298 
  
     
Calibration Hosmer-
Lemeshow test 
X2 = 4.499 
(p = 0.810) 
X2 = 10.769 
(p = 0.216) 
X2 = 6.718 
(p = 0.577) 
X2 = 4.483 
(p = 0.810) 
X2 = 5.845 
(p = 0.701) 
  




correction 0.966 0.912 0.937 0.914 0.905 
  
     
Model 
coefficients 
(uncorrected) Intercept -4.482 -4.595 -3.935 -6.813 -11.478 
 
Oral cavity MD 
(Gy) 0.054 0.042 0.056 0.040 X 
 Parotid cont. 
MD (Gy) 0.036 x x x X 
 PCM sup MD 
(Gy) x x x x 0.105 
 PCM inf MD 
(Gy) x x x x 0.041 
 T3 or T4 x 1.492 x x 1.549 
 Weight loss BL 
>10% x 1.110 x x 1.544 
 Dry mouth BL 
Gr 1 x x 0.927 x x 
 Concomitant 













 Age (years) x x x 0.043 x 
 Accelerated RT x x x 1.122 x 
 
ROC=receiver operating curve; AUC=are under curve; R2=linear regression coefficient squared. MD=mean dose; PCM=pharyngeal constrictor muscles; 
sup=superior; inf=inferior; T=T stage; BL=at baseline; RT=radiotherapy; CI=confidence interval. 
 
*Events are the patients in the whole dataset that had the endpoint at 6 months (i.e., the prevalence in the whole group). Both controls and those with 






















































Interval of the 














≥2 6.7 6.7 + 3.6 




14.2 (5.2 - 
31.2) -8.318 -9.431 -7.205 < 0.001 < 0.001 
Dysphagia grade 
≥3 3.3 4.9 + 4.4 
3 (1.5 - 
16.3) 7.6 + 5.7 
5.3 (3.4 - 









17.3 (8.4 - 




3.3 4.7 + 3.3 3.8 (1.3 - 15.4) 7.6 + 4.7 
6.1 (2.6 - 
23.2) -2.857 -3.534 -2.180 < 0.001 < 0.001 
Tube dependence 0 1.3 + 1.7 0.6 (0.1 - 6.2) 1.7 + 2.5 
0.7 (0.1 - 
11.1) -0.419 -0.890 0.052 0.079 0.005 
 















































































































Approaches to predict upfront the potential clinical gains of a new technology or approach in radiation 
delivery are needed in a rapidly advancing field. This study reports on an outcomes-based predictive 
model of anticipated gains (xerostomia and dysphagia) for proton therapy in the treatment of oropharynx 
cancer. These results and this approach can be used to complement prospective trials, or to rationalize 
novel treatment approaches when randomized data are not yet available.  
 
